Lisa Kriegl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lisa Kriegl has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Stefan Hatzl
Intensive Care Unit, Department of Internal Medicine, Medical University of Graz , Graz
10 shared publications - Robert Krause
BioTechMed Graz , Graz
9 shared publications - Philipp Eller
Intensive Care Unit, Department of Internal Medicine, Medical University of Graz , Graz
7 shared publications - Christina Geiger
Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz , Graz
5 shared publications Markus Keldorfer
Department of Children and Adolescent Medicine, Pediatric Intensive Care Unit, Medical University of Graz , Graz
4 shared publicationsChristina Geiger
Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz , Graz
3 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Empirical Antifungal Treatment of Critically Ill Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Bayesian Perspective
We reanalyzed 172 critically ill patients with influenza-associated ARDS in a Bayesian framework. Empirical mold-active antifungal treatment yielded a posterior median hazard ratio for influenza-associated pulmonary aspergillosis of 0.51 (95% credible interval 0.20-1.17; probability of benefit 94%), without mortality benefit. Findings remained consistent across skeptical, non-informative and externally informed priors.
- 17 October 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessEmpirical Antifungal Treatment of Critically Ill Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Bayesian Perspective
We reanalyzed 172 critically ill patients with influenza-associated ARDS in a Bayesian framework. Empirical mold-active antifungal treatment yielded a posterior median hazard ratio for influenza-associated pulmonary aspergillosis of 0.51 (95% credible interval 0.20-1.17; probability of benefit 94%), without mortality benefit. Findings remained consistent across skeptical, non-informative and externally informed priors.
- Open Access
- 26 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Epidemiology and Economic Burden of Puumala Virus Infection in Styria, Austria, 2003 to 2024
Background: Hantavirus infections cause hemorrhagic fever with renal syndrome and impose a potential burden on healthcare systems. However, comprehensive economic data remain scarce. We quantified the inpatient economic burden of hospitalized patients with Puumala virus (PUUV) infections in Styria, Austria’s primary endemic region, to identify hospitalization costs and early admission predictors of costs. Methods: This retrospective cost-of-illness study analyzed 1049 serologically confirmed PUUV hospitalizations across 20 public hospitals in Styria, Austria between September 2003 and March 2024. Costs were estimated using the Austrian performance-oriented hospital financing (Leistungsorientierte Krankenanstaltenfinanzierung) diagnosis-related group system, standardized to 2024-equivalent Euros using consumer price index deflation. Admission predictors of cost were assessed using multivariable γ-generalized linear modeling with multiple imputations. Temporal trends in length of stay were analyzed using weighted segmented linear regression. Results: Cumulative inpatient cost was ∼€10.3 million (mean per-case: €9788) for the entire study period of 21 years. Three epidemic years (2012, 2019, and 2021) accounted for 53.6% of cases and over €5.2 million in expenditure, with peak annual costs reaching €1.93 million (0.274% of total Styrian inpatient expenditure) in 2012. Prolonged activated partial thromboplastin time (aPTT; cost-ratio 1.024 per second, 95% CI 1.019–1.030) and older age (CR 1.004 per year, 95% CI 1.001–1.008) were independent admission-level predictors of higher cost. Median hospital length of stay declined by ∼50% over the study period. Conclusions: PUUV hospitalizations impose a sharply episodic but recurrent economic burden on regional healthcare systems. Admission aPTT and age independently predicted cost, but clinical outcomes were not modeled and these variables do not constitute a triage tool. Epidemic preparedness strategies are warranted.
- 26 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Open AccessEpidemiology and Economic Burden of Puumala Virus Infection in Styria, Austria, 2003 to 2024
Background: Hantavirus infections cause hemorrhagic fever with renal syndrome and impose a potential burden on healthcare systems. However, comprehensive economic data remain scarce. We quantified the inpatient economic burden of hospitalized patients with Puumala virus (PUUV) infections in Styria, Austria’s primary endemic region, to identify hospitalization costs and early admission predictors of costs. Methods: This retrospective cost-of-illness study analyzed 1049 serologically confirmed PUUV hospitalizations across 20 public hospitals in Styria, Austria between September 2003 and March 2024. Costs were estimated using the Austrian performance-oriented hospital financing (Leistungsorientierte Krankenanstaltenfinanzierung) diagnosis-related group system, standardized to 2024-equivalent Euros using consumer price index deflation. Admission predictors of cost were assessed using multivariable γ-generalized linear modeling with multiple imputations. Temporal trends in length of stay were analyzed using weighted segmented linear regression. Results: Cumulative inpatient cost was ∼€10.3 million (mean per-case: €9788) for the entire study period of 21 years. Three epidemic years (2012, 2019, and 2021) accounted for 53.6% of cases and over €5.2 million in expenditure, with peak annual costs reaching €1.93 million (0.274% of total Styrian inpatient expenditure) in 2012. Prolonged activated partial thromboplastin time (aPTT; cost-ratio 1.024 per second, 95% CI 1.019–1.030) and older age (CR 1.004 per year, 95% CI 1.001–1.008) were independent admission-level predictors of higher cost. Median hospital length of stay declined by ∼50% over the study period. Conclusions: PUUV hospitalizations impose a sharply episodic but recurrent economic burden on regional healthcare systems. Admission aPTT and age independently predicted cost, but clinical outcomes were not modeled and these variables do not constitute a triage tool. Epidemic preparedness strategies are warranted.
- Open Access
- 2 July 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (4)
Population pharmacokinetics, target attainment and individualized dosing of isavuconazole in critically ill adults receiving extracorporeal membrane oxygenation
Background and Objectives: Patients receiving extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome are at high risk of invasive pulmonary aspergillosis, but isavuconazole population pharmacokinetics and target attainment during ECMO remain incompletely characterized. To characterize isavuconazole population pharmacokinetics during ECMO, quantify between-patient variability and the probability of target attainment (PTA) and derive dosing implications. Patients and methods: Fifteen critically ill adults receiving ECMO and intravenous isavuconazole were studied prospectively, with 148 plasma concentrations measured over 168 h. First loading doses of 200, 300 or 400 mg reflected a stepwise change in institutional practice and were followed in all patients by 200 mg q8h × 5 and 200 mg q24h. Individual parameters were estimated by Bayesian forecasting against a literature-informed prior, and PTA was evaluated by simulating 5000 virtual subjects under five maintenance regimens. Results: Loading-phase exposure increased with the first dose (median AUC0–24 14.2, 26.1 and 33.5 mg·h/L; P = 0.025) and converged at steady-state. Median Bayesian apparent clearance was 4.06 L/h, comparable with non-ECMO ICU populations, but between-patient variability was substantially wider (coefficient of variation 116% versus 38%; range 0.77–15.73 L/h). AUC0–τ ≥ 60 mg·h/L was attained in four of seven patients with an evaluable steady-state profile, and simulation projected 41% attainment under standard maintenance. No regimen achieved >80% efficacy and >80% safety PTA simultaneously. Eight patients (53%) died. Conclusions: ECMO did not alter isavuconazole population clearance, so routine dose escalation is not warranted. Wide between-patient variability precludes any fixed regimen and favours therapeutic drug monitoring-guided individualized dosing.
- 2 July 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (4)
Open AccessPopulation pharmacokinetics, target attainment and individualized dosing of isavuconazole in critically ill adults receiving extracorporeal membrane oxygenation
Background and Objectives: Patients receiving extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome are at high risk of invasive pulmonary aspergillosis, but isavuconazole population pharmacokinetics and target attainment during ECMO remain incompletely characterized. To characterize isavuconazole population pharmacokinetics during ECMO, quantify between-patient variability and the probability of target attainment (PTA) and derive dosing implications. Patients and methods: Fifteen critically ill adults receiving ECMO and intravenous isavuconazole were studied prospectively, with 148 plasma concentrations measured over 168 h. First loading doses of 200, 300 or 400 mg reflected a stepwise change in institutional practice and were followed in all patients by 200 mg q8h × 5 and 200 mg q24h. Individual parameters were estimated by Bayesian forecasting against a literature-informed prior, and PTA was evaluated by simulating 5000 virtual subjects under five maintenance regimens. Results: Loading-phase exposure increased with the first dose (median AUC0–24 14.2, 26.1 and 33.5 mg·h/L; P = 0.025) and converged at steady-state. Median Bayesian apparent clearance was 4.06 L/h, comparable with non-ECMO ICU populations, but between-patient variability was substantially wider (coefficient of variation 116% versus 38%; range 0.77–15.73 L/h). AUC0–τ ≥ 60 mg·h/L was attained in four of seven patients with an evaluable steady-state profile, and simulation projected 41% attainment under standard maintenance. No regimen achieved >80% efficacy and >80% safety PTA simultaneously. Eight patients (53%) died. Conclusions: ECMO did not alter isavuconazole population clearance, so routine dose escalation is not warranted. Wide between-patient variability precludes any fixed regimen and favours therapeutic drug monitoring-guided individualized dosing.
- Open Access
- 18 November 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (12) , ofaf709
Triazoles Versus Echinocandins for the First-Line Treatment of Invasive Pulmonary Aspergillosis: A Propensity Score–Weighted Multicenter Study
Background: Triazoles (eg, isavuconazole, posaconazole, voriconazole) are the first-line treatment for invasive pulmonary aspergillosis (IPA), but their use can be limited by drug interactions, hepatotoxicity, and emerging azole resistance. Recent guidelines recommend echinocandins as a safe and well-tolerated first-line alternative. Methods: In this multicenter observational study across 9 treatment centers, we included all consecutive patients with IPA from 1 January 2014 to 1 June 2024. We compared 30-day overall survival (OS) as the primary outcome and 90-day OS as the secondary outcome between patients receiving triazoles versus echinocandins as first-line therapy. Propensity score adjustment was applied to address baseline characteristic imbalances. Results: We included 177 patients, of whom 153 (86%) received triazoles as first-line therapy (69 voriconazole, 54 isavuconazole, 30 posaconazole). Before propensity score adjustment, patients treated with echinocandins were significantly sicker, with higher rates of intensive care treatment (95% vs 75%, P = .002). In both crude and propensity score–adjusted analyses, 30-day mortality was significantly higher in the echinocandin group compared to the triazole group (63% [95% CI 55–70] vs 30% [95% CI 13–50], P < .001). Even switching from echinocandins after initial treatment failure to salvage therapy did not mitigate the negative impact on OS. Switching from triazoles (28/153 cases) was mainly due to tolerability concerns, while echinocandins (12 cases) were switched for treatment failure. Conclusions: Using echinocandins as alternative first-line treatment for IPA may result in poorer survival outcomes and should be approached with caution until further trials confirm our findings.
- 18 November 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (12) , ofaf709
Open AccessTriazoles Versus Echinocandins for the First-Line Treatment of Invasive Pulmonary Aspergillosis: A Propensity Score–Weighted Multicenter Study
Background: Triazoles (eg, isavuconazole, posaconazole, voriconazole) are the first-line treatment for invasive pulmonary aspergillosis (IPA), but their use can be limited by drug interactions, hepatotoxicity, and emerging azole resistance. Recent guidelines recommend echinocandins as a safe and well-tolerated first-line alternative. Methods: In this multicenter observational study across 9 treatment centers, we included all consecutive patients with IPA from 1 January 2014 to 1 June 2024. We compared 30-day overall survival (OS) as the primary outcome and 90-day OS as the secondary outcome between patients receiving triazoles versus echinocandins as first-line therapy. Propensity score adjustment was applied to address baseline characteristic imbalances. Results: We included 177 patients, of whom 153 (86%) received triazoles as first-line therapy (69 voriconazole, 54 isavuconazole, 30 posaconazole). Before propensity score adjustment, patients treated with echinocandins were significantly sicker, with higher rates of intensive care treatment (95% vs 75%, P = .002). In both crude and propensity score–adjusted analyses, 30-day mortality was significantly higher in the echinocandin group compared to the triazole group (63% [95% CI 55–70] vs 30% [95% CI 13–50], P < .001). Even switching from echinocandins after initial treatment failure to salvage therapy did not mitigate the negative impact on OS. Switching from triazoles (28/153 cases) was mainly due to tolerability concerns, while echinocandins (12 cases) were switched for treatment failure. Conclusions: Using echinocandins as alternative first-line treatment for IPA may result in poorer survival outcomes and should be approached with caution until further trials confirm our findings.
- Open Access
- 15 September 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (3) , e485-e493
Empirical Antifungal Treatment of Critically Ⅲ Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
Background: Influenza-associated pulmonary aspergillosis (IAPA) is a significant fungal complication in patients with influenza-induced acute-respiratory-distress-syndrome (ARDS). The impact of empirical antifungal treatment on IAPA incidence and outcomes remains unclear. Methods: In this observational multicenter study (9 treatment centers), we included all consecutive patients admitted to intensive care units (ICUs) with influenza-associated ARDS between 1 September 2016 and 1 March 2025. We compared patients receiving empirical antifungal treatment with those who did not, focusing on 30-day IAPA incidence (primary outcome) and survival (secondary outcome). Propensity score weighting was used to account for baseline characteristic imbalances. IAPA cases were classified based on the Fungal-Infections-in-Adult-Patients-in-ICU (FUNDICU) consensus criteria. Results: We included 172 patients, 61 (35%) of whom received empirical antifungal therapy (94% posaconazole). IAPA was diagnosed in 24 cases, with a median onset of 2 days after ICU admission. Of these, 20 occurred in the non-treatment group and 4 in the empirical treatment group. The 30-day IAPA incidence was 7.7% in the treatment group and 20.4% in the non-treatment group (P = .002). The sub-distributional hazard ratio (sHR) for IAPA incidence in the empirical treatment group compared with the non-treatment group was 0.21 (95% CI: 0.10–0.92, P = .045). However, there was no significant difference in 30-day ICU survival. Conclusions: In ICU patients with influenza ARDS, empirical antifungal treatment was associated with significantly reduced IAPA incidence, but this did not translate into improved survival. Randomized controlled trials are warranted to evaluate the efficacy and safety of patients’ specific empirical antifungal treatment with regard to IAPA incidence and outcomes.
- 15 September 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (3) , e485-e493
Open AccessEmpirical Antifungal Treatment of Critically Ⅲ Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
Background: Influenza-associated pulmonary aspergillosis (IAPA) is a significant fungal complication in patients with influenza-induced acute-respiratory-distress-syndrome (ARDS). The impact of empirical antifungal treatment on IAPA incidence and outcomes remains unclear. Methods: In this observational multicenter study (9 treatment centers), we included all consecutive patients admitted to intensive care units (ICUs) with influenza-associated ARDS between 1 September 2016 and 1 March 2025. We compared patients receiving empirical antifungal treatment with those who did not, focusing on 30-day IAPA incidence (primary outcome) and survival (secondary outcome). Propensity score weighting was used to account for baseline characteristic imbalances. IAPA cases were classified based on the Fungal-Infections-in-Adult-Patients-in-ICU (FUNDICU) consensus criteria. Results: We included 172 patients, 61 (35%) of whom received empirical antifungal therapy (94% posaconazole). IAPA was diagnosed in 24 cases, with a median onset of 2 days after ICU admission. Of these, 20 occurred in the non-treatment group and 4 in the empirical treatment group. The 30-day IAPA incidence was 7.7% in the treatment group and 20.4% in the non-treatment group (P = .002). The sub-distributional hazard ratio (sHR) for IAPA incidence in the empirical treatment group compared with the non-treatment group was 0.21 (95% CI: 0.10–0.92, P = .045). However, there was no significant difference in 30-day ICU survival. Conclusions: In ICU patients with influenza ARDS, empirical antifungal treatment was associated with significantly reduced IAPA incidence, but this did not translate into improved survival. Randomized controlled trials are warranted to evaluate the efficacy and safety of patients’ specific empirical antifungal treatment with regard to IAPA incidence and outcomes.
- Open Access
- 28 April 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf256
Lateral Flow Device Aspergillus Routine Testing for Invasive Pulmonary Aspergillosis in Patients Who Are Critically Ill: A Multicenter Intensive Care Unit Cohort Study
Background: The incidence of invasive pulmonary aspergillosis (IPA) is rising among intensive care unit (ICU) patients, with early diagnosis and treatment being critical for survival. Lateral flow assays for Aspergillus antigen detection have recently been introduced, enabling rapid results within an hour and potentially supporting earlier clinical decision making and timely antifungal therapy. Methods: This retrospective multicenter study included 180 ICU patients, 48 with IPA and 132 controls, across 9 treatment centers. Fungal infections were classified according to the FUNDICU criteria (Invasive Fungal Diseases in Adult Patients in Intensive Care Unit). Results: Among the 180 patients, 48 were classified as having probable IPA, while 132 exhibited host factors and radiologic findings consistent with IPA but did not meet the FUNDICU criteria. In this cohort, the sensitivity and specificity of the bronchoalveolar lavage lateral flow device test for diagnosing probable IPA vs no IPA were 71% (95% CI, 56%–83%) and 98% (94%–100%), respectively. The area under the receiver operating characteristic curve was 0.84, indicating good diagnostic performance. The positive and negative likelihood ratios were 31.17 (10.03–96.80) and 0.30 (.19–.46), yielding a diagnostic odds ratio of 104 (30–360). The positive and negative predictive values were 92% (78%–98%) and 90% (84%–95%). Conclusions: Lateral flow device testing may serve as a valuable tool for the rapid diagnosis of IPA in time-critical ICU settings. However, it is not sufficient to definitively rule out the disease, and a comprehensive diagnostic approach remains essential.
- 28 April 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf256
Open AccessLateral Flow Device Aspergillus Routine Testing for Invasive Pulmonary Aspergillosis in Patients Who Are Critically Ill: A Multicenter Intensive Care Unit Cohort Study
Background: The incidence of invasive pulmonary aspergillosis (IPA) is rising among intensive care unit (ICU) patients, with early diagnosis and treatment being critical for survival. Lateral flow assays for Aspergillus antigen detection have recently been introduced, enabling rapid results within an hour and potentially supporting earlier clinical decision making and timely antifungal therapy. Methods: This retrospective multicenter study included 180 ICU patients, 48 with IPA and 132 controls, across 9 treatment centers. Fungal infections were classified according to the FUNDICU criteria (Invasive Fungal Diseases in Adult Patients in Intensive Care Unit). Results: Among the 180 patients, 48 were classified as having probable IPA, while 132 exhibited host factors and radiologic findings consistent with IPA but did not meet the FUNDICU criteria. In this cohort, the sensitivity and specificity of the bronchoalveolar lavage lateral flow device test for diagnosing probable IPA vs no IPA were 71% (95% CI, 56%–83%) and 98% (94%–100%), respectively. The area under the receiver operating characteristic curve was 0.84, indicating good diagnostic performance. The positive and negative likelihood ratios were 31.17 (10.03–96.80) and 0.30 (.19–.46), yielding a diagnostic odds ratio of 104 (30–360). The positive and negative predictive values were 92% (78%–98%) and 90% (84%–95%). Conclusions: Lateral flow device testing may serve as a valuable tool for the rapid diagnosis of IPA in time-critical ICU settings. However, it is not sufficient to definitively rule out the disease, and a comprehensive diagnostic approach remains essential.
- Open Access
- 12 February 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (4)
It's Friday, 3 p.m., and the phone rings ... a practical approach to common nephrology consultations—Part 1
This practical approach highlights the importance of timely recognition and management of various nephrological emergencies. The featured conditions pose an extraordinary challenge, since their recognition, timely workup and immediate bedside management are often only roughly pictured in guidelines. This article provides case-based insights and highlights pitfalls with regards to current guidelines on the management of acute conditions frequently managed by nephrologists. The first case, acute allograft dysfunction, underscores the critical need to distinguish between various etiologies of acute kidney injury (AKI) to guide targeted interventions effectively. Case 2 explores the challenges of managing acute infections in kidney transplant recipients, highlighting the necessity of tailoring immunosuppressive therapy, conducting a thorough diagnostic workup, and ensuring timely and adequate treatment. Case 3 focuses on the recognition and management of pulmonary-renal syndrome, emphasizing the importance of initiating serological testing, planning for biopsy, and administering empirical immunosuppressive therapy. In Case 4, a structured and pragmatic approach to diagnosis and treatment of thrombotic microangiopathy, with an emphasis on identifying potential pitfalls to prevent delays in therapy is given. Case 5 focuses AKI in pregnancy, a high-stakes condition that requires prompt and comprehensive diagnostic evaluation to minimize risks to both mother and child. Finally, Case 6 presents a diagnostic and treatment framework for managing suspected infections of a tunneled hemodialysis catheter, aiming to optimize outcomes through early and effective interventions.
- 12 February 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (4)
Open AccessIt's Friday, 3 p.m., and the phone rings ... a practical approach to common nephrology consultations—Part 1
This practical approach highlights the importance of timely recognition and management of various nephrological emergencies. The featured conditions pose an extraordinary challenge, since their recognition, timely workup and immediate bedside management are often only roughly pictured in guidelines. This article provides case-based insights and highlights pitfalls with regards to current guidelines on the management of acute conditions frequently managed by nephrologists. The first case, acute allograft dysfunction, underscores the critical need to distinguish between various etiologies of acute kidney injury (AKI) to guide targeted interventions effectively. Case 2 explores the challenges of managing acute infections in kidney transplant recipients, highlighting the necessity of tailoring immunosuppressive therapy, conducting a thorough diagnostic workup, and ensuring timely and adequate treatment. Case 3 focuses on the recognition and management of pulmonary-renal syndrome, emphasizing the importance of initiating serological testing, planning for biopsy, and administering empirical immunosuppressive therapy. In Case 4, a structured and pragmatic approach to diagnosis and treatment of thrombotic microangiopathy, with an emphasis on identifying potential pitfalls to prevent delays in therapy is given. Case 5 focuses AKI in pregnancy, a high-stakes condition that requires prompt and comprehensive diagnostic evaluation to minimize risks to both mother and child. Finally, Case 6 presents a diagnostic and treatment framework for managing suspected infections of a tunneled hemodialysis catheter, aiming to optimize outcomes through early and effective interventions.
- Open Access
- 13 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf018
Pulmonary Coinfection of Pneumocystis jirovecii and Aspergillus Species
In this multicenter study of 387 patients who were immunocompromised, 4.5% with invasive pulmonary aspergillosis also had Pneumocystis jirovecii pneumonia. Predictors of coinfection included elevated β-D-glucan and prolonged corticosteroid use. Coinfection correlated with reduced 30-day survival (22% vs 57%), suggesting that early identification and prophylaxis may improve outcomes.
- 13 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf018
Open AccessPulmonary Coinfection of Pneumocystis jirovecii and Aspergillus Species
In this multicenter study of 387 patients who were immunocompromised, 4.5% with invasive pulmonary aspergillosis also had Pneumocystis jirovecii pneumonia. Predictors of coinfection included elevated β-D-glucan and prolonged corticosteroid use. Coinfection correlated with reduced 30-day survival (22% vs 57%), suggesting that early identification and prophylaxis may improve outcomes.
- Open Access
- 20 December 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (5) , 1080-1087
Performance of Diagnostic Algorithms in Patients With Invasive Pulmonary Aspergillosis
Background: Invasive pulmonary aspergillosis (IPA), once limited to immunocompromised patients, is now a severe complication in critically ill ICU patients without classic risk factors. Due to the difficulty of obtaining histological evidence, diagnosis relies on poorly tested algorithms in real-world settings. Methods: We conducted a retrospective multicenter (n = 9) cohort study including 202 patients with IPA. Patients were classified using a multistep process based on the EuropeanOrganization- for-the-Research-and-Treatment-of-Cancer/Mycosis-Study Group (EORTC-MSG), Invasive-Fungal-Diseases-in-Adult-Patients-in-Intensive-Care-Unit (FUNDICU), Aspergillus-ICU (Asp-ICU), and Asp-ICU with biomarkers (Asp-ICU-BM) criteria. We then evaluated the predictive performance of these criteria against the clinical cohort and histologically proven cases. Results: Among 202 patients, 78 had EORTC-MSG host factors and were classified accordingly, with EORTC-MSG criteria achieving 100% agreement in identifying clinical and histologically proven cases. In 112 ICU patients without EORTC-MSG host factors, overall agreement was 53% for FUNDICU, 4% for Asp-ICU, and 26% for Asp-ICU-BM versus the clinical cohort. Validation against histologically proven cases showed FUNDICU had 44% sensitivity and 75% specificity, Asp-ICU 6% sensitivity and 100% specificity, and Asp-ICU-BM 28% sensitivity and 63% specificity. Adding acute respiratory distress syndrome (ARDS) and post-cardiac surgery to the FUNDICU criteria improved sensitivity to 97% with a specificity of 63%. The remaining 12 patients lacked EORTC-MSG host factors and were not in the ICU, highlighting a novel classification system. Conclusions: EORTC-MSG and FUNDICU IPA classification systems are useful for the assignment of most patients with IPA. Incorporating postoperative complications after cardiac surgery and ARDS enhanced the diagnostic accuracy of FUNDICU.
- 20 December 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (5) , 1080-1087
Open AccessPerformance of Diagnostic Algorithms in Patients With Invasive Pulmonary Aspergillosis
Background: Invasive pulmonary aspergillosis (IPA), once limited to immunocompromised patients, is now a severe complication in critically ill ICU patients without classic risk factors. Due to the difficulty of obtaining histological evidence, diagnosis relies on poorly tested algorithms in real-world settings. Methods: We conducted a retrospective multicenter (n = 9) cohort study including 202 patients with IPA. Patients were classified using a multistep process based on the EuropeanOrganization- for-the-Research-and-Treatment-of-Cancer/Mycosis-Study Group (EORTC-MSG), Invasive-Fungal-Diseases-in-Adult-Patients-in-Intensive-Care-Unit (FUNDICU), Aspergillus-ICU (Asp-ICU), and Asp-ICU with biomarkers (Asp-ICU-BM) criteria. We then evaluated the predictive performance of these criteria against the clinical cohort and histologically proven cases. Results: Among 202 patients, 78 had EORTC-MSG host factors and were classified accordingly, with EORTC-MSG criteria achieving 100% agreement in identifying clinical and histologically proven cases. In 112 ICU patients without EORTC-MSG host factors, overall agreement was 53% for FUNDICU, 4% for Asp-ICU, and 26% for Asp-ICU-BM versus the clinical cohort. Validation against histologically proven cases showed FUNDICU had 44% sensitivity and 75% specificity, Asp-ICU 6% sensitivity and 100% specificity, and Asp-ICU-BM 28% sensitivity and 63% specificity. Adding acute respiratory distress syndrome (ARDS) and post-cardiac surgery to the FUNDICU criteria improved sensitivity to 97% with a specificity of 63%. The remaining 12 patients lacked EORTC-MSG host factors and were not in the ICU, highlighting a novel classification system. Conclusions: EORTC-MSG and FUNDICU IPA classification systems are useful for the assignment of most patients with IPA. Incorporating postoperative complications after cardiac surgery and ARDS enhanced the diagnostic accuracy of FUNDICU.
- Open Access
- 8 May 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae270
Antifungals in Patients With Extracorporeal Membrane Oxygenation: Clinical Implications
Extracorporeal membrane oxygenation (ECMO) is a life-saving technique used in critical care medicine for patients with severe respiratory or cardiac failure. This review examines the treatment and prophylaxis of fungal infections in ECMO patients, proposing specific regimens based on available data for different antifungals (azoles, echinocandins, amphotericin B/liposomal amphotericin B) and invasive fungal infections. Currently, isavuconazole and posaconazole have the most supported data, while modified dosages of isavuconazole are recommended in ECMO. Echinocandins are preferred for invasive candidiasis. However, choosing echinocandins is challenging due to limited and varied data on concentration loss in the ECMO circuit. Caution is likewise advised when using liposomal amphotericin B due to uncertain concentrations and potential ECMO dysfunction based on scarce data. We further conclude with the importance of further research on the impact of ECMO on antifungal drug concentrations to optimize dosing regimens in critically ill patients.
- 8 May 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae270
Open AccessAntifungals in Patients With Extracorporeal Membrane Oxygenation: Clinical Implications
Extracorporeal membrane oxygenation (ECMO) is a life-saving technique used in critical care medicine for patients with severe respiratory or cardiac failure. This review examines the treatment and prophylaxis of fungal infections in ECMO patients, proposing specific regimens based on available data for different antifungals (azoles, echinocandins, amphotericin B/liposomal amphotericin B) and invasive fungal infections. Currently, isavuconazole and posaconazole have the most supported data, while modified dosages of isavuconazole are recommended in ECMO. Echinocandins are preferred for invasive candidiasis. However, choosing echinocandins is challenging due to limited and varied data on concentration loss in the ECMO circuit. Caution is likewise advised when using liposomal amphotericin B due to uncertain concentrations and potential ECMO dysfunction based on scarce data. We further conclude with the importance of further research on the impact of ECMO on antifungal drug concentrations to optimize dosing regimens in critically ill patients.